PATENT CLAIM ANALYSIS

Application Number: 16047071
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["548", "112000"]

Abstract:
The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Claim (Index 62):
A method for treating a subject afflicted with cancer comprising administering to the subject a therapeutically effective amount of:\n a) a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof, and b) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 95.0
- Lexical Diversity: 1.32432
- Patent Class: 548.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12716187', '11251490', '10891362', '11787165', '14265943']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7031400657227821
- 35 USC 102 Novelty (BERT): 0.5160166093383429
- Combined Prediction Score: 0.6844277200843383
- Mean Citation Score: 262.89877
- Max Citation Score: 275.15298
- Similarity Product: 181.73790091930388

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test